Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR3 | P49682 | 2/20 | 0.58 |
| ▸ | HPGD | P15428 | 2/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | MMP13 | P45452 | 1/20 | 0.54 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.53 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.53 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.53 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.53 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.53 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.53 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.53 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.53 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.53 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.53 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | VCP | P55072 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL483635 | 1.00 | CXCR3 (0.58) | CXCR3HPGDSMN1; SMN2L3MBTL1MMP13 | |
| SCHEMBL11757383 | 0.92 | SMN1; SMN2 (0.64) | CXCR3HPGDSMN1; SMN2L3MBTL1MMP13 | |
| SCHEMBL11760297 | 0.92 | SMN1; SMN2 (0.64) | CXCR3HPGDSMN1; SMN2L3MBTL1MMP13 | |
| SCHEMBL4396197 | 0.87 | SMN1; SMN2 (0.60) | CXCR3HPGDSMN1; SMN2L3MBTL1MMP13 | |
| SCHEMBL8598520 | 0.83 | HDAC3 (0.64) | HPGDSMN1; SMN2HDAC3HDAC4HDAC1 | |
| SCHEMBL7487285 | 0.83 | HDAC3 (0.64) | HPGDSMN1; SMN2HDAC3HDAC4HDAC1 | |
| Hydrochloric Acid SCHEMBL27583097 | 0.81 | HTR4 (0.60) | CXCR3HPGDSMN1; SMN2L3MBTL1MMP13 | |
| SCHEMBL30989205 | 0.81 | VCP (0.61) | HPGDSMN1; SMN2ALDH1A1VCPGAA | |
| SCHEMBL10185047 | 0.81 | NPC1 (0.55) | HPGDSMN1; SMN2L3MBTL1ALDH1A1GAA | |
| SCHEMBL4005112 | 0.81 | MAPK14 (0.55) | CXCR3HPGDSMN1; SMN2L3MBTL1MMP13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 100 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12551418-B2 | Cosmetic containing ultraviolet wavelength converting substance and medicinal agent | SHISEIDO COMPANY, LTD. (JP) | 2026-02-17 | — | — | US | disclosed |
| EP-3389595-B1 | COMBINATION OF POLYION COMPLEX PARTICLE AND NON-POLYMERIC ACID HAVING TWO OR MORE ACID DISSOCIATION CONSTANTS | OREAL (FR) | 2025-11-05 | — | — | EP | disclosed |
| CN-120131453-A | W/O/W type emulsified composition | 株式会社资生堂 | 2025-06-13 | — | — | CN | disclosed |
| EP-4554549-A1 | COMPOSITION COMPRISING SKIN CARE ACTIVE INGREDIENT OR CELLULOSE COMPOUND | L'OREAL (FR) | 2025-05-21 | — | — | EP | disclosed |
| EP-3638192-B1 | COMBINATION OF POLYION COMPLEX PARTICLE AND NON-POLYMERIC ACID OR BASE HAVING TWO OR MORE DISSOCIATION CONSTANTS | OREAL (FR) | 2025-04-02 | — | — | EP | disclosed |
| CN-119730833-A | Melanogenesis inhibitor | 一丸自然美健有限公司 | 2025-03-28 | — | — | CN | disclosed |
| CN-119677492-A | Composition comprising a skin care active or a cellulose compound | 莱雅公司 | 2025-03-21 | — | — | CN | disclosed |
| EP-3638201-B1 | COMBINATION OF POLYION COMPLEX PARTICLE AND NON-POLYMERIC BASE HAVING TWO OR MORE DISSOCIATION CONSTANTS | OREAL (FR) | 2025-02-26 | — | — | EP | disclosed |
| WO-2024203441-A1 | POWDERY SOLID COSMETIC | 株式会社 資生堂 | 2024-10-03 | — | — | WO | disclosed |
| US-12029303-B2 | Method for preparation of a cosmetic kit | SHISEIDO COMPANY, LTD. (JP) | 2024-07-09 | — | — | US | disclosed |
| US-20090047312-A1 | Microgel and external compositions containing the same | SHISEIDO CO., LTD. (JP) | 2009-02-19 | — | — | US | disclosed |
| US-20080124367-A1 | Oil Based Composition For External Use On Skin For Enhancing Percutaneous Absorption | SHISEIDO COMPANY, LTD. (JP) | 2008-05-29 | — | — | US | disclosed |
| EP-1894558-A1 | AGENT FOR EXTERNAL APPLICATION TO THE SKIN | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo (JP) | 2008-03-05 | — | — | EP | disclosed |
| EP-1839647-A1 | OILY SKIN COMPOSITION FOR EXTERNAL USE FOR ACCELERATING PERCUTANEOUS ABSORPTION | SHISEIDO COMPANY, LTD. (JP) | 2007-10-03 | — | — | EP | disclosed |
| EP-1402875-A1 | POWDERY COMPOSITION | SHISEIDO COMPANY, LTD. (JP) | 2004-03-31 | — | — | EP | disclosed |
| US-20040028710-A1 | Process for producing dry water | SHISEIDO COMPANY, LTD. (JP) | 2004-02-12 | — | — | US | disclosed |
| EP-1386599-A1 | PROCESS FOR PRODUCING DRY WATER | SHISEIDO COMPANY, LTD. (JP) | 2004-02-04 | — | — | EP | disclosed |
| US-20030202993-A1 | Powdery composition | SHISEIDO COMPANY, LTD. (JP) | 2003-10-30 | — | — | US | disclosed |
| EP-1158021-A1 | MICROGELS AND EXTERNAL PREPARATIONS CONTAINING THE SAME | SHISEIDO COMPANY LIMITED (JP) | 2001-11-28 | — | — | EP | disclosed |
| EP-1002515-A1 | SKIN COMPOSITIONS FOR EXTERNAL USE | SHISEIDO COMPANY LIMITED (JP) | 2000-05-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12551418-B2 | Cosmetic containing ultraviolet wavelength converting substance and medicinal agent | GLA, PGA5, AGER | CXCR3 3508/4885HPGD 132/4885SMN1; SMN2 3929/4885 |
| US-20030202993-A1 | Powdery composition | CUTA, FLNA, FERMT2 | CXCR3 3593/4885HPGD 4241/4885SMN1; SMN2 1453/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.